This trial is active, not recruiting.

Condition coronary heart disease
Treatment pharmacist follow-up
Sponsor Hospital Pharmacy of North Norway Trust
Collaborator University of Tromso
Start date February 2009
End date June 2011
Trial size 200 participants
Trial identifier NCT01115608, SHAN-001


It is well known that secondary prevention is very important for patients with established coronary heart disease, it reduces both mortality and morbidity. Pharmacists in Norway are not routinely involved in follow-up of this patient group, but many studies have shown that involvement of a pharmacist have a positive influence in achieving therapy goals for e.g. blood pressure, lipids and blood sugar.

The investigators hypothesis is that follow-up by a clinical pharmacist after hospital discharge will increase adherence to clinical guideline recommendations and increase achievement of specific therapy goals for blood pressure, lipids and glucose in patients with established CHD. The investigators plan to include patients with established CHD, discharged from hospital after admission to the cardiology department.

Patients included (18-80 years) will be randomized to an intervention and a control group. In addition to ordinary health care, the intervention group receives follow-up from a clinical pharmacist during one year with three meeting points, at discharge, after three months and after one year. The control group receives only ordinary health care, but are called in after one year for data collection. Patients living in nursing homes, patients already receiving pharmaceutical follow-up elsewhere and cancer patients are excluded from the study. Only patients living in the area of Tromsoe and nearby is included, as they need to physically see the pharmacist.

The follow-up include medication review and subsequently solving of drug related problems in addition to drug information and monitoring of clinical therapy goals relevant for secondary prevention of CHD.

The main outcome measures is adherence to specified review criteria defined in a medication assessment tool (MAT-CHDsp) based on recommendations from the European Society of Cardiology. Other outcome measures include 1)number of drug related problems identified and solved, 2) hospital admissions, 3)deaths.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking open label
Primary purpose health services research
The patients will receive pharmaceutical follow-up during one year after discharge from the hospital. Three meetings are arranged, one at discharge, one after three months and the last after one year. Patients will be called up for arrangement of "consultation". Written information concerning drugs used will be supplied.
pharmacist follow-up
Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
(No Intervention)
The control group receives no follow-up from the pharmacist, but will after one year, when they are out of the study, receive one follow-up visit and drug review.

Primary Outcomes

Adherence to MAT-CHDsp (medication assessment tool based on guideline recommendations)
time frame: At baseline (both arms)
Adherence to MAT-CHDsp (medication assessment tool based on guideline recommendations)
time frame: After one year (both arms)

Secondary Outcomes

Drug related problems
time frame: At inclusion, after three months and after one year.
time frame: After one year

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - established coronary heart disease - age 18 - 80 years - patients living in the three nearby communities Tromsoe, Balsfjord and Karlsoey, this because they need to see the pharmacist personally. Exclusion Criteria: - patients living in nursing homes - patients included in NORstent, another trial including patients at the same department - patients already receiving pharmaceutical follow-up elsewhere - cancer patients

Additional Information

Official title Development of a Standardized Clinical Pharmacist Service for Patients Discharged From Hospital. Measurement of Drug Prescribing Quality in Secondary Prevention of Coronary Heart Disease Utilizing a Medication Assessment Tool (MAT-CHDsp)
Trial information was received from ClinicalTrials.gov and was last updated in May 2011.
Information provided to ClinicalTrials.gov by Hospital Pharmacy of North Norway Trust.